Robeco Institutional Asset Management B.V. Buys 86,494 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Robeco Institutional Asset Management B.V. grew its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 691,607 shares of the medical research company's stock after purchasing an additional 86,494 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.18% of Thermo Fisher Scientific worth $344,144,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of TMO. Bernard Wealth Management Corp. purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at about $25,000. Pillar Financial Advisors LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth $29,000. Ameriflex Group Inc. bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $30,000. Noble Wealth Management PBC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $35,000. Finally, Cassady Schiller Wealth Management LLC raised its stake in shares of Thermo Fisher Scientific by 89.2% in the fourth quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company's stock valued at $36,000 after acquiring an additional 33 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have issued reports on TMO. Stifel Nicolaus lowered their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Evercore ISI reduced their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Argus lowered their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Finally, Barclays decreased their target price on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating for the company in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $604.05.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Up 0.3%

NYSE:TMO traded up $1.37 during trading hours on Thursday, reaching $412.02. The company's stock had a trading volume of 2,926,073 shares, compared to its average volume of 1,955,518. The business's 50-day moving average is $410.39 and its 200-day moving average is $485.33. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.77 and a quick ratio of 1.38. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The company has a market cap of $155.53 billion, a price-to-earnings ratio of 24.17, a price-to-earnings-growth ratio of 2.13 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same quarter in the previous year, the firm earned $5.11 EPS. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.42%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.